Ascendis Pharma (ASND1N) Financial Statements
Ascendis Pharma Financial Overview
Ascendis Pharma's market cap is currently $294.54B. The company's EPS TTM is $12.10; its P/E ratio is 18.53; Ascendis Pharma is estimated to report earnings on November 11, 2026, and the estimated EPS forecast is $16.49. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 691.71M | $ 363.64M | $ 266.72M | $ 51.17M | $ 7.78M |
| Gross Profit | $ 588.53M | $ 319.38M | $ 222.32M | $ 39.04M | $ 4.25M |
| Operating Income | $ -130.89M | $ -278.76M | $ -455.54M | $ -561.81M | $ -451.79M |
| EBITDA | $ -109.80M | $ -290.02M | $ -411.17M | $ -529.18M | $ -364.64M |
| Net Income | $ -219.03M | $ -378.08M | $ -481.45M | $ -583.19M | $ -383.58M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 615.78M | $ 559.54M | $ 399.44M | $ 735.46M | $ 682.06M |
| Total Assets | $ 1.30B | $ 1.18B | $ 825.59M | $ 1.09B | $ 1.08B |
| Total Debt | $ 871.41M | $ 856.62M | $ 743.06M | $ 617.57M | $ 209.92M |
| Net Debt | $ 255.64M | $ 297.07M | $ 350.89M | $ 172.80M | $ -236.34M |
| Total Liabilities | $ 1.46B | $ 1.29B | $ 971.28M | $ 826.39M | $ 201.29M |
| Stockholders' Equity | $ -162.75M | $ -105.71M | $ -145.70M | $ 263.35M | $ 883.63M |
| Cash Flow | |||||
| Free Cash Flow | $ 43.62M | $ -307.62M | $ -469.80M | $ -510.19M | $ -441.88M |
| Operating Cash Flow | $ 51.77M | $ -306.20M | $ -467.36M | $ -495.70M | $ -417.65M |
| Investing Cash Flow | $ -8.15M | $ 6.88M | $ 286.47M | $ 61.73M | $ -110.58M |
| Financing Cash Flow | $ 34.89M | $ 443.93M | $ 134.29M | $ 396.77M | $ 351.39M |
Currency in EUR
